Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67120 | 1.00 | CA1 (0.33) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL2160514 | 1.00 | CA1 (0.33) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL28058555 | 0.98 | CA1 (0.32) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL26449280 | 0.89 | MMP13 (0.31) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL26449237 | 0.89 | MMP13 (0.31) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL23749797 | 0.87 | HDAC6 (0.32) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL26449279 | 0.87 | HDAC6 (0.32) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL26449223 | 0.87 | HDAC6 (0.32) | CA1CA2CA7AAK1MMP13 | |
| SCHEMBL6843570 | 0.87 | AAK1 (0.32) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL1486172 | 0.87 | AAK1 (0.32) | AAK1MMP13MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | claimed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4558507-B1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-0760822-A1 | ANTI-FUNGAL CYCLIC DEPSIPEPTIDES | SCHERING CORPORATION (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0408973-B1 | Antiherpes pentapeptides | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1996-10-23 | — | — | EP | disclosed |
| US-5552384-A | Antiherpes compositions and method of use | BIO-MEGA BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-09-03 | — | — | US | disclosed |
| US-5502036-A | VIRICIDES | BIOMEGA BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-03-26 | — | — | US | disclosed |
| WO-1995030692-A1 | ANTI-FUNGAL CYCLIC DEPSIPEPTIDES | SCHERING CORPORATION (US) | 1995-11-16 | — | — | WO | disclosed |
| EP-0411334-B1 | Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-02-22 | — | — | EP | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0493770-A2 | Antiherpes compositions | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | disclosed |
| EP-0411334-A1 | Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | CA1 1379/4885CA2 627/4885CA7 895/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | CA1 317/4885CA2 354/4885CA7 1209/4885 |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DMPK, KRTCAP2 | CA1 2190/4885CA2 1027/4885CA7 744/4885 |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, MALT1, LY6K | CA1 336/4885CA2 492/4885CA7 173/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | CA1 1996/4885CA2 403/4885CA7 162/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | CA1 409/4885CA2 1262/4885CA7 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.